Kenneth Herwig, MD
Cardiovascular Disease · New York, NYNPI 1205932415
Payments from drug & device makers
Across 58 payments — averaging $44.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$587
- Amgen$389
- Boston Scientific$268
- AbbVie$251
- Sanofi-aventis U.S. LLC$243
- Johnson & Johnson$150
- plus $681 from 9 others
What the payments were for
- Food & beverage$2,569100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $587 |
| Amgen | 19 | $389 |
| Boston Scientific | 2 | $268 |
| AbbVie(2 entities) | 2 | $251 |
| Sanofi-aventis U.S. LLC | 2 | $243 |
| Johnson & Johnson | 8 | $150 |
| Scpharmaceuticals Inc. | 1 | $149 |
| Medtronic | 1 | $130 |
| Corcept Therapeutics | 1 | $125 |
| Agepha Pharma FZ LLC | 1 | $120 |
| Novartis | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Optinose US, Inc. | 1 | $24 |
| AstraZeneca | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$251
- MULTAQ$243
- LifeVest$236
- FUROSCIX$149
- GENERAL TACHY$145
- Reveal LINQ$130
- Korlym$125
- Watchman$123
- LODOCO$120
How this compares
$2,569 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $12,467 |
| Metoprolol Succinate | 62 | $974 |
| Valsartan | 28 | $628 |
| Atorvastatin Calcium | 91 | $542 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $332 |
| Losartan Potassium | 48 | $223 |
| Rosuvastatin Calcium | 20 | $215 |
| Amlodipine Besylate | 35 | $190 |
| Famotidine | 29 | $173 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.